Methamphetamine: User Characteristics and Treatment Response Alice Huber, Ph.D. Steven Shoptaw, Ph.D. Richard A. Rawson, Ph.D. Paul Brethen, M.A. Walter.

Slides:



Advertisements
Similar presentations
XR-NTX Implementation in Los Angeles County Desirée A. Crèvecoeur-MacPhail, PhD UCLA Integrated Substance Abuse Programs Santa Monica Blvd., Suite.
Advertisements

Gender Differences in Sexual Behavior and Attitudes among Opiate, Alcohol, Cocaine, and Methamphetamine Users Richard A. Rawson, PhD 1 Chris Reiber, PhD,
Gender Differences in Health Status Among Opiate Users in a 25-Year Follow-up Study Christine Grella & Luz Rodriguez UCLA Integrated Substance Abuse Programs.
What is the evidence for time limiting addiction treatment?
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Differences in Characteristics of Heroin Inhalers and Injectors at Admission to Treatment J. C. Maxwell, R. T. Spence, & T. M. Bohman UT Center for Social.
Substance Use: Substance use comparisons included lifetime and past 30 day use (Figure 3) and lifetime use. For past 30 day use, more men reported heroin.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
Treatment of Methamphetamine Dependence: Does Treatment Work? Mary Lynn Brecht, Ph.D. Richard A. Rawson, Ph.D Semel Institute for Neuroscience and Human.
Treatment of Methamphetamine Dependence: A brief overview Richard A. Rawson, Ph.D Adjunct Associate Professor Semel Institute for Neuroscience and Human.
Methamphetamine A Post-War Epidemic FACTORS Large quantities Disorganization “Work pills” 500,000 addicts Reduced supply Increased heroin JAPAN.
UCLA Drug Abuse Research CenterForever Free Evaluation Forever Free Substance Abuse Treatment Program Outcomes Study Michael Prendergast, Ph.D., Principal.
TERMINATION OF LONG-TERM MENTAL HEALTH TREATMENT WITH FOSTER YOUTH Kimberlin Borca, Foster Care Research Group University of San Francisco April 29, 2012.
Research Strategies to Test Behavioral/Psychotherapy Treatments for Substance Use Disorders: Several Examples Richard A. Rawson, Ph.D UCLA ISAP Cairo,
Addictions Treatment Planning for Effectiveness CSD 5970.
UCLA Integrated Substance Abuse Programs (ISAP). CSAT MTP Project Goals: To study the clinical effectiveness of the Matrix Model To study the clinical.
Practical Application of Contingency Management Michael J. McCann, MA Matrix Institute on Addictions.
Audrey J. Brooks, PhD University of Arizona CA-AZ node.
Using Research/Evaluation Questions to Define Data Collection and Findings: Findings from the FY 2004 KTOS Follow-up Study Robert Walker, Allison Mateyoke-Scrivener,
Developing Surveillance for Alcohol Abuse, Dependence, and Related Consequences in New Mexico Sandra Woerle, MA New Mexico Department of Health Office.
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
Suboxone as an Adjunctive Medication, Not Maintenance Dennis M. Donovan, Ph.D. UW Alcohol & Drug Abuse Institute Patricia C. Knox, Ph.D. Recovery Centers.
ILLINOIS STATEWIDE TREATMENT OUTCOMES PROJECT. Illinois Statewide Treatment Outcomes Project Largest evaluation of treatment outcomes by the State to.
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
Greenberg&Cohen EBCRP Methamphetamine: Understanding the Influence of Violence in Treatment Planning and Recovery Judith Cohen, PhD Rivka Greenberg, PhD.
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
C:\laam\lamAPA.ppt 8/04/98 Heroin Addiction Treatment: A Comparison of Methadone and LAAM M. Douglas Anglin, Ph.D. Douglas Longshore, Ph.D. Jeffrey J.
Results of the Vivitrol Pilot in Los Angeles County Presented by: Desiree A. Crevecoeur-MacPhail, Ph.D. Research Psychologist, UCLA ISAP.
Does reduction in cocaine use represent psychosocial benefit? Ivan D. Montoya, M.D., M.P.H. Deputy Director, NIDA-DPMC.
METHODS Sample n=245 Women, 24% White, 72% Average age, 36.5 Never married, 51% Referral Sources (%) 12-Month DSM-IV Substance Dependence Prior to Entering.
Outcomes of Treatment for Methamphetamine Use: LA County (“Treatment-as-Usual”) M.-L. Brecht UCLA Integrated Substance Abuse Programs CATES 3/30/2004.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
Obtaining housing associated with achieving abstinence after detoxification in adults with addiction Tae Woo Park, Christine Maynié-François, Richard Saitz.
Recovery Support Services and Client Outcomes: What do the Data Tell Us? Recovery Community Services Program Grantee Meeting December 14, 2007.
CARIBBEAN BASIN AND HISPANIC ADDICTION TECHNOLOGY TRANSFER CENTER Effects of a Two-facet Intervention to Reduce HIV Risk Behaviors Among Hispanic Drug.
APPLIED PSYCHOLOGY LABORATORY East Tennessee State University Johnson City, Tennessee INTRODUCTION CONTACT:
TRI science addiction Profiles of OxyContin Users Deni Carise, PH.D. Treatment Research Institute, University of Pennsylvania San Antonio, TX. October,
CCTN September 6 th, Recent Scientific Publications from the Clinical Trials Network David Liu, M.D. (CTN-0029) Harold Perl, Ph.D. (CTN-0015) Paul.
Harold I Perl, PhD National Institute on Drug Abuse APA 120 th Annual Convention August 3, 2012.
Unhealthy alcohol use in other drug users identified by screening in primary care Secondary analysis of ASPIRE trial data Funded by NIDA 1 R01 DA
Raymond F. Anton, MD for The COMBINE Study Research Group
Participants were recruited from 6 drug free, psychosocial treatment (PT) and 5 methadone maintenance (MM) programs (N = 628) participating in a NIDA Clinical.
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
Reducing Sex under the Influence for Substance Abuse Treatment Patients Symposium Presentation at the American Psychological Association Annual Convention,
Introduction Introduction Alcohol Abuse Characteristics Results and Conclusions Results and Conclusions Analyses comparing primary substance of abuse indicated.
Introduction Results and Conclusions Categorical group comparisons revealed no differences on demographic or social variables. At admission to treatment,
Introduction Results and Conclusions On demographic variables, analyses revealed that ATR clients were more likely to be Hispanic and employed, whereas.
Treatment for Methamphetamine Abuse and Dependence Richard A. Rawson, Ph.D. Alice Huber, Ph.D. Paul Brethen, M.A. Walter Ling, M.D. Matrix/UCLA/LAARC Supported.
Abstinence Incentive Effects in Psychosocial Counseling Patients Testing Stimulant Positive vs Negative at Treatment Entry Maxine L. Stitzer Johns Hopkins.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
California Addiction Training and Education Series Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute on Addictions Methamphetamine Behavioral.
Introduction Results and Conclusions Analyses of demographic and social variables revealed that women were more likely to have children, be living in a.
Smoking and Mental Health Problems in Treatment-Seeking University Students Eric Heiligenstein, M.D. University of Wisconsin-Madison Health Services Stevens.
Texas COSIG Project Gender Differences in Substance Use Severity and Psychopathology in Clients with Co-Occurring Disorders 5 th Annual COSIG Grantee Meeting.
TREATMENT OF SUBSTANCE USE DISORDERS TX myths 1. Nothing works 2. One approach is superior to all others (“one true light” tradition) 3. All treatment.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Predictors of study retention in addiction treatment trials KORTE JE 1, MAGRUDER KM 1,2, KILLEEN TK 1, SONNE SC 1, SAMPSON RR 1 and BRADY KT 1,2 1. Medical.
Kathryn P. Jett Director California Department of Alcohol and Drug Programs.
Brain diseases: Substance abuse and co-occurring disorders Mark Publicker, MD FASAM.
J. Aaron Johnson, PhD 1 and J. Paul Seale, MD 2 1 Institute of Public and Preventive Health and Department of Psychology, Georgia Regents University, Augusta,
BEHAVIORAL FAMILY COUNSELING AND NALTREXONE FOR MALE OPIOID-DEPENDENT PATIENTS William Fals-Stewart, Ph.D. Research Institute on Addictions.
Association for Women in Psychology Conference “A Model of Integrated Treatment for Women with Co-Occurring Disorders who are at High Risk for HIV” Presented.
TOMS/NOMS FY12- FY14 Adult Survey Analysis: Does treatment lead to changes over time? 2/16/2016 Prepared by: Abigail Howard, Ph.D.
Introduction Results and Conclusions Numerous demographic variables were found to be associated with treatment completion. Completers were more likely.
Recidivism Rates for DCJ Offenders Exiting Residential Treatment June 2007 Kim Pascual Research & Evaluation.
A comprehensive evaluation of post- mortem findings and psychiatric case records of individuals who died by probable suicide. A van Laar, J Kielty, M Davoren,
Trends in Access to Substance Abuse Treatment for Women and Men: Jeanne C. Marsh, PhD, Hee-Choon Shin, PhD, Dingcai Cao, PhD University of Chicago.
Course of Alcohol Use Disorders: Data from a 35 Year Follow Up
Efforts to Reduce Meth Use and Sexual Risk
Center for Behavioral Health Statistics and Quality
Presentation transcript:

Methamphetamine: User Characteristics and Treatment Response Alice Huber, Ph.D. Steven Shoptaw, Ph.D. Richard A. Rawson, Ph.D. Paul Brethen, M.A. Walter Ling, M.D. Matrix Center / LAATRC Research supported by NIDA R

Topics of Discussion n Project overview n Characteristics of methamphetamine users n Description of treatment process n Response to treatment model n Implications

Project Overview n Matrix clinic in Rancho Cucamonga n Located in San Bernardino County u 50 miles east of Los Angeles n Significant stimulant abuse in past decade n Matrix model of treatment u Standardized treatment n Comprehensive chart review

Project Overview n Charts of all stimulant users included n Clients entered treatment between n Large sample u 500 methamphetamine users u 224 cocaine users n Demographics, drug use information, urine toxicology, and treatment outcome ratings

Participant Characteristics MA UsersCOC Users n Gender * 60.0% Male68.8% Male n Ethnicity * u Caucasian80.5%48.0% u Hispanic16.7%15.8% u Afr Amer 1.9%34.2% n Education (yrs) * * all tests p<.01 * all tests p<.01

Participant Characteristics MA UsersCOC Users n Age at Admission * n Marital Status * u Never Married48.9%36.1% u Married25.8%37.5% u Sep/Div/Widow25.3%26.4%

Participant Characteristics MA UsersCOC Users n Employment Status * u Work Full Time27.5%31.2% u Work Part Time10.8%17.6% u Not Working61.6%50.9% n Type of Employment * u White Collar 15.1%18.3% u Blue Collar84.9%81.7%

Alcohol Use MA UsersCOC Users n Alcohol * u > 1 day/week 22.5%31.1% u Weekly/Monthly 43.7%48.8% u None 33.8%20.1% n Standard Drinks/Occasion * u 1-2 Drinks 29.4%24.8% u 3-6 Drinks 51.4%46.6% u > 6 Drinks 17.9%28.6% * all tests p<.01 * all tests p<.01

Alcohol Use MA UsersCOC Users n With Drug of Choice * 34.3% 46.9% 34.3% 46.9% n Need Alcohol Treatment? * 12.6%24.6% 12.6%24.6% * all tests p<.01 * all tests p<.01

Other Substance Use MA UsersCOC Users n Cocaine, past yr.10.8%100.0% n Meth, past yr.100.0%17.9% n Marijuana, past yr. * 56.2%42.4% n Halluc./PCP, past yr. * 6.4%0.0% n Barbiturates, past yr.2.8%2.2%

Drug Use Information MA UsersCOC Users n Age First Used * n Heavy Use 41.2 mos.39.7 mos. n Route * u Intranasal55.5%21.5% u Smoking7.2%48.0% u Multiple Routes 22.7%16.7% u Any IV use13.5%13.1%

Drug Use Information MA UsersCOC Users n Frequency of Use * u None in 30 days14.8%17.4% u 1-2 times/week24.8%44.6% u 3-6 times/week17.0%16.8% u daily43.6%21.2% n Recent Use * u Days / past mo u Money / past mo.$123$275 n Longest Abstinence * 1-2 mos.2-3 mos.

Drug Use Information MA UsersCOC Users n Believe they are addicted * 82.1% 89.6% addicted * 82.1% 89.6% n Had prior treatment for drug use * 24.6%44.7% for drug use * 24.6%44.7% * all tests p<.01 * all tests p<.01

Self-Reported Medical Problems MA UsersCOC Users n Chest pain29.8%25.5% n Headaches * 42.4%32.8% n Seizures2.0%4.2% n Loss of consciousness7.7%6.5% n Need medical tx.10.7%5.8% NOTE: Answers reflect current medical problems.

Self-Reported Psych Problems MA UsersCOC Users n Previous psych tx.14.4%16.5% n Current psych problems u Depressed, “a lot” * 19.3%12.1% u Suicide thoughts * 6.9%2.8% u Hallucinations * 34.8%25.1% u Paranoid thoughts28.8%25.5% NOTE: Answers reflect current psychiatric problems.

Comparisons of IV/non-IV Users IV UsersOther Users n Use > 3g/ week * 38.1%11.4% n Use daily * 65.1%40.1% n Severe withdrawal * 36.5%22.0% n Buy direct / deal * 33.3%13.2%

Comparisons of IV/non-IV Users IV UsersOther Users n Felony convictions * 36.8%17.4% n No Family Rels. * 22.2%5.8% n Bankruptcy * 44.3%19.3% n Unemployed > 1yr. * 58.0%28.2%

Comparisons of IV/non-IV Users IV UsersOther Users n Hallucinations/paranoia * 55.5%33.2% n Seizures/loss of consc * 30.2%14.2% n Problems with Sex * 29.7%12.8% n Drug/sex connected * 22.5%9.6%

Summary of User Characteristics n Typical user is an unemployed male Caucasian, with a high school education n Higher percentage of MA users are female and married, compared to Cocaine users n Started using drug at younger age; entered treatment at younger age n Primary route was intranasal, now see more smokers; most use daily

Summary of User Characteristics n More likely using other drugs; less likely to be using alcohol n Fewer feel “addicted”, despite more involvement with other users n Medical and psychological problems u Hallucinations very common u Appear more psychiatrically disturbed and more out of control u May be physically sicker

Treatment: Matrix Model n Combination of individual, family, and group sessions n Program to last 6 months n Strong emphasis on cognitive-behavioral approach n Designed in phases that decrease in intensity

Treatment Services Received MA UsersCOC Users n Individual Sessions13.3 hrs.16.3 hrs. n Stabilization Group3.4 hrs.3.7 hrs. n Relapse Prevention 23.7 hrs.21.0 hrs. n Family Education11.6 hrs.12.2 hrs. n Social Support 4.4 hrs.4.3 hrs.

Urinalysis Results n Tested randomly, about once a week u Samples not always collected when patient self- reported drug use MA usersCOC users MA usersCOC users n Number of urine samples collected samples collected n Percent positive (dirty) for drug of choice 10.4% 8.1% for drug of choice 10.4% 8.1%

Treatment Retention

Summary of Treatment Findings n A structured, manualized psychosocial treatment program is a viable treatment for methamphetamine abuse/dependence n This treatment retains more than 50% of patients for a clinically meaningful treatment episode

Summary of Treatment Findings n Response to treatment for MA addicts is not different than that seen in cocaine addicts n Equal numbers of drug-positive urines n Retention is similar for both groups n A significant percentage of stimulant addicts do not complete treatment successfully

Treatment Outcome n Current project measures primarily the response to a particular model n Follow-up necessary to evaluate treatment outcome n Center for Substance Abuse Treatment has funded a follow-up study with this group of patients

Follow-up Project n Randomly select 100 methamphetamine and 100 cocaine patients from the sample n Admissions from n Contact for in-person interview, ASI, medical and psychiatric symptom report, and urine sample n Expect completion of project in 2/97

Implications n Methamphetamine a serious drug problem n The use of methamphetamine continues to increase, even in areas where it has been available for years n Methamphetamine use is initiated at a younger age n Methamphetamine may be somewhat more popular among women

Implications n Now see more addicts who smoke methamphetamine n Addicts may turn to smoking and then intravenous routes as their history of use lengthens n Some routes (particularly IV use) associated with more serious physical, psychological, psychosocial, and societal outcomes

Implications n Psychosocial treatment can be quite effective for some addicts n Even extended psychosocial treatment leave a significant percentage of addicts impaired n Need to develop psychosocial and pharmacological approaches specific to methamphetamine